脾切除术治疗复发/难治自身免疫性溶血性贫血的疗效
回顾性分析30例复发/难治AIHA患者行脾切除术的疗效,术后10~14天20例可评价者ORR为90%;13例长期随访中,10例纯AIHA术后6个月和12个月ORR分别为90%和70%,中位随访14个月。
要点
- 脾切除术后10~14天可评价的20例患者ORR为90%,其中CR 12例、PR 6例。
- 10例复发/难治纯AIHA术后6个月和12个月ORR分别为90%和70%。
- 3例患者持续完全缓解3年以上,约占可长期随访纯AIHA患者的三分之一。
核心结论
- 脾切除术作为复发/难治AIHA的二线治疗近期疗效好,1年远期ORR达70%,约三分之一患者可维持长期持续缓解。
研究设计与样本
- 回顾性分析中国医学科学院血液病医院30例行脾切除术治疗的复发/难治AIHA患者的临床资料。
- 30例中单纯AIHA 20例(温抗体型13例、温冷双抗体型2例、Coombs阴性AIHA 5例),Evans综合征10例。
- 术后10~14天评估短期疗效,并随访术前术后血常规指标及疗效。
主要发现
- 术后10~14天20例可评价疗效,ORR为90%(CR 12例,PR 6例)。
- 13例有长期随访资料,中位随访14(4~156)个月。
- 除3例Evans综合征患者死亡外(2例无效,1例复发),10例复发/难治纯AIHA术后6个月9例(90%)有效,术后12个月7例(70%)有效。
- 截至随访终点,3例患者已持续完全缓解3年以上。
临床怎么用
- 原文结论认为脾切除术作为二线方案治疗复发/难治AIHA近期疗效好,1年远期ORR达到70%,约三分之一患者可维持长期持续缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the outcomes of splenectomy in the treatment of relapsed/refractory autoimmune hemolytic anemia (AIHA). Methods: Retrospective analysis was performed in 30 cases with relapsed/refractory AIHA who were treated with splenectomy in our hospital. The pre- and post-operative blood routine indexes and responses were followed up. Results: Among the 30 relapsed/refractory AIHA patients, 20 were pure AIHA (including 13 patients with warm antibody AIHA, 2 with warm-cold double antibody AIHA and 5 with Coombs negative AIHA) and 10 were Evans syndrome. The short-term response was evaluated 10-14 days after operation, and the overall response rate (ORR) of short-term response was 90% [12 cases in complete response (CR), 6 cases in partial response (PR)] in 20 therapeutic evaluable cases. Among 13 patients with long-term follow-up data, except 3 patients with Evans syndrome died (2 cases were refractory to splenectomy, 1 case relapsed after surgery), the ORR of 10 patients with relapsed/refractory pure AIHA at 6 months and 12 months were 90% (9/10) and 70% (7/10), respectively, with a median follow-up of 14 (4-156) months. At the end of follow-up, 3 cases had maintained CR for more than 3 years. Conclusion: The short-term response of splenectomy as a second-line treatment for relapsed/refractory AIHA is satisfactory, and long-term outcome of splenectomy is up to 70% at 1 year. Approximately one-third of patients could maintain sustained remission. 目的: 评估脾切术治疗复发/难治自身免疫性溶血性贫血(AIHA)患者的疗效。 方法: 回顾性分析中国医学科学院血液病医院30例行脾切除术治疗的复发/难治自身免疫性溶血性贫血(AIHA)患者的临床资料,评估手术疗效。 结果: 30例复发/难治AIHA患者中,单纯AIHA 20例(温抗体型13例,温冷双抗体型2例,Coombs阴性AIHA 5例),Evans综合征10例。脾切除术后10~14 d,20例患者可评价疗效,总有效率(ORR)为90%(完全缓解12例,部分缓解6例)。13例患者有长期随访资料,中位随访14(4~156)个月,截至随访终点,除3例Evans综合征患者死亡外(2例无效,1例复发),10例复发/难治AIHA患者术后6个月9例(90%)有效,术后12个月7例(70%)有效,其中3例患者已持续完全缓解3年以上。 结论: 脾切除术作为二线方案治疗复发/难治AIHA近期疗效好,1年远期ORR达到70%,约三分之一患者可维持长期持续缓解。.
引用
- Fan SB, Wang ZJ, Mao Q, et al. [Outcomes of splenectomy in relapsed/refractory autoimmune hemolytic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 30831628. doi:10.3760/cma.j.issn.0253-2727.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。